Tag - Platelet BioGenesis

Platelet BioGenesis Appoints Leading Hematology Experts and Physicians to Its Scientific Advisory Board

Ziad2022-11-25T14:05:04-05:00Platelet BioGenesis, the leader in the production of functional human platelets (PLTs+TM) from stem cells and the development of platelet-based therapeutics, announced it has recruited a team of world-renowned experts to its newly formed scientific advisory board. Read more >>

Platelet BioGenesis Licenses Induced Pluripotent Stem Cell Technology from iPS Academia Japan

Ziad2022-11-25T14:05:05-05:00Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>

Platelet BioGenesis Licenses Induced Pluripotent Stem Cell Technology from iPS Academia Japan

Ziad2022-11-25T14:05:05-05:00Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>

iCons Works at Fall Workshop

Ziad2022-11-25T14:05:17-05:00About 100 iCons scholars and applicants gathered in the Integrative Learning Center of UMass Amherst on Nov 9, 2017 for the annual iCons Fall Integrative Workshop. They came to hear Dr. Jonathan Thon tell the story of how his start-up company Platelet Biogenesis came to be. Integrated Concentration in Science (iCons) Program Director Justin Fermann introduced Thon to the crowd, telling the iCons students “we are here because we have work to do, and he’s got some problems we need...

BioPharm America™ 2017: Platelet BioGenesis generating platelets on demand

Ziad2022-11-25T14:05:29-05:00Platelets are the bandaids of the bloodstream. Every year more than two million people in the US receive platelet transfusions as part of cancer treatment, transplants and surgery. Unfortunately, platelets are at high risk of bacterial or viral contamination, and have a very short shelf life. We spoke to Sven Karlsson of Platelet BioGenesis, an exciting company and winner of the BioPharm America startup competition, that has developed a ex vivo system for generating immune compatible platelets on demand. Read...

Platelet Biogenesis Raises a $10 Million Series A Financing Led by Qiming U.S. Healthcare Fund

Ziad2022-11-25T14:05:42-05:00Platelet BioGenesis, a biotech startup developing a process to produce life-saving human platelets from stem cells for therapeutic applications, announced it has successfully raised $10 million in Series A financing. Read more >>